Kimberly D Pringle1, Maritza Patzi2, Jacqueline E Tate3, Volga Iniguez Rojas4, Manish Patel3, Lucia Inchauste Jordan4, Raul Montesano5, Adolfo Zarate2, Lucia De Oliveira6, Umesh Parashar3. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Programa Ampliado de Inmunización, Ministerio de Salud. 3. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases. 4. Facultad de Ciencias Puras y Naturales, Instituto de Biología Molecular y Biotecnología, Universidad Mayor de San Andrés. 5. Pan American Health Organization, La Paz, Bolivia. 6. Pan American Health Organization, Washington D.C.
Abstract
BACKGROUND: In Bolivia, monovalent rotavirus vaccine was introduced in 2008 and a previous evaluation reported a vaccine effectiveness (VE) of 77% with 2 doses of vaccine in children aged <3 years. This evaluation sought to determine if rotavirus vaccine provided protection through the second year of life against circulating genotypes. METHODS: A case-control study was performed in 5 hospitals from April 2013 to March 2014. Among enrolled participants who met study criteria and had rotavirus stool testing performed and vaccine status confirmed, we calculated VE using a logistic regression model. Subgroup analyses were performed among children aged <1 year and those aged ≥1 year, among children with severe diarrhea (Vesikari score ≥11) and very severe diarrhea (Vesikari score ≥15), and among G and P strains with at least 40 specimens. RESULTS: A total of 776 children were enrolled. For children <1 year and ≥1 year of age with severe diarrhea, VE for 2 doses was 75% (95% confidence interval [CI], 46%-88%) and 53% (95% CI, 9%-76%), respectively. For children <1 year and ≥1 year of age with very severe diarrhea, VE for 2 doses was 80% (95% CI, 44%-93%) and 74% (95% CI, 35%-90%), respectively. Genotype-specific analysis demonstrated similar VE for the 4 most common G and P types (G3, G9, P[6] and P[8]). CONCLUSIONS: A monovalent rotavirus vaccine remains effective against a broad range of circulating strains as part of a routine immunization program >5 years after its introduction in Bolivia. Although VE appears to wane in children aged ≥1 year, it still provides significant protection, and does not wane against severe disease. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: In Bolivia, monovalent rotavirus vaccine was introduced in 2008 and a previous evaluation reported a vaccine effectiveness (VE) of 77% with 2 doses of vaccine in children aged <3 years. This evaluation sought to determine if rotavirus vaccine provided protection through the second year of life against circulating genotypes. METHODS: A case-control study was performed in 5 hospitals from April 2013 to March 2014. Among enrolled participants who met study criteria and had rotavirus stool testing performed and vaccine status confirmed, we calculated VE using a logistic regression model. Subgroup analyses were performed among children aged <1 year and those aged ≥1 year, among children with severe diarrhea (Vesikari score ≥11) and very severe diarrhea (Vesikari score ≥15), and among G and P strains with at least 40 specimens. RESULTS: A total of 776 children were enrolled. For children <1 year and ≥1 year of age with severe diarrhea, VE for 2 doses was 75% (95% confidence interval [CI], 46%-88%) and 53% (95% CI, 9%-76%), respectively. For children <1 year and ≥1 year of age with very severe diarrhea, VE for 2 doses was 80% (95% CI, 44%-93%) and 74% (95% CI, 35%-90%), respectively. Genotype-specific analysis demonstrated similar VE for the 4 most common G and P types (G3, G9, P[6] and P[8]). CONCLUSIONS: A monovalent rotavirus vaccine remains effective against a broad range of circulating strains as part of a routine immunization program >5 years after its introduction in Bolivia. Although VE appears to wane in children aged ≥1 year, it still provides significant protection, and does not wane against severe disease. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Jennifer J Hull; Elizabeth N Teel; Tara K Kerin; Molly M Freeman; Mathew D Esona; Jon R Gentsch; Margaret M Cortese; Umesh D Parashar; Roger I Glass; Michael D Bowen Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: L H De Oliveira; N Giglio; A Ciapponi; S García Martí; M Kuperman; N J Sanwogou; C Ruiz-Matus; M F Marinho de Sousa Journal: Vaccine Date: 2013-07-02 Impact factor: 3.641
Authors: Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Jailson B Correia; Manish M Patel; Osamu Nakagomi; Fernanda M U Montenegro; Eliane M Germano; Nancy B Correia; Luis E Cuevas; Umesh D Parashar; Nigel A Cunliffe; Toyoko Nakagomi Journal: J Infect Dis Date: 2010-02-01 Impact factor: 5.226
Authors: Manish M Patel; Maritza Patzi; Desiree Pastor; Aleida Nina; Yelin Roca; Leovigildo Alvarez; Volga Iniguez; Rosario Rivera; Ka Ian Tam; Osbourne Quaye; Michael Bowen; Umesh Parashar; Lucia Helena De Oliveira Journal: BMJ Date: 2013-06-19
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Rachel M Burke; Jacqueline E Tate; Kimberly D Pringle; Manish Patel; Lucia H De Oliveira; Umesh D Parashar Journal: Pediatr Infect Dis J Date: 2018-08 Impact factor: 2.129
Authors: Jordan E Cates; Avnika B Amin; Jacqueline E Tate; Ben Lopman; Umesh Parashar Journal: Pediatr Infect Dis J Date: 2021-12-01 Impact factor: 2.129
Authors: K Zaman; David A Sack; Kathleen M Neuzil; Mohammad Yunus; Lawrence H Moulton; Jonathan D Sugimoto; Jessica A Fleming; Ilias Hossain; Shams El Arifeen; Tasnim Azim; Mustafizur Rahman; Kristen D C Lewis; Andrea J Feller; Firdausi Qadri; M Elizabeth Halloran; Alejandro Cravioto; John C Victor Journal: PLoS Med Date: 2017-04-18 Impact factor: 11.069